Could Gilead Make A Profit From Remdesivir?
Roche’s Tamiflu Was A Pandemic Blockbuster, But COVID-19 Is Different
Executive Summary
All being well, Gilead could gain emergency approval for remdesivir by early May - but arriving at a 'reasonable' price and devising rapid access programs will be a major challenge.
You may also be interested in...
Gilead Ramps Up Remdesivir Manufacturing, Advances Inhaled Formulation
Gilead will study inhalable remdesivir in volunteers, then hopefully in August as an earlier COVID-19 treatment. Analyst says production of 2m-plus I.V. doses by year-end could mean blockbuster revenues.
Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.
Apparent China Study Failure May Not Spell End For Remdesivir COVID-19 Role
Apparently disappointing results from the world’s first randomized study for Gilead's remdesivir in COVID-19 have some wondering about whether antiviral can still play a decisive role in some patients with COVID-19.